Clinical trial
SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer…
NCT00102726 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00102726 |
|---|---|
| Title | SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy |
| Official title | A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist(SB497115-GR) Administered at 50, 75, and 100 mg to Cancer Patients Receiving Multiple Cycles of Chemotherapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thrombocytopaenia |
| Intervention type | Drug, Other |
| Interventions | SB497115, Placebo |
| Enrollment | 183 |
| Start date | Feb 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Feb 2, 2005 |
| Last update posted | Mar 23, 2017 |
| Countries | Argentina, Austria, Bulgaria, Czechia, Germany, Hungary, India, Italy, Mexico, Peru, Poland, Romania and 7 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: